Clinical trial
Trial of Iressa in Prostate Cancer Patients
NCT00265070 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00265070 |
|---|---|
| Title | Trial of Iressa in Prostate Cancer Patients |
| Official title | An Open-Label, Phase II Trial Of 250 mg ZD1839 (IRESSA™) In Prostate Cancer Patients With Early Biochemical Failure Post Prostatectomy |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Gefitinib |
| Enrollment | 80 |
| Start date | Jan 1, 2003 |
| Completion | Aug 1, 2011 |
| First posted | Dec 14, 2005 |
| Last update posted | Feb 5, 2013 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: